Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 20/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18968210 | 1.00 | PADI4 (0.61) | PADI4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18969429 | 0.93 | PADI4 (0.71) | PADI4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18969426 | 0.93 | PADI4 (0.71) | PADI4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20121131 | 0.93 | PADI4 (0.71) | PADI4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20121132 | 0.93 | PADI4 (0.71) | PADI4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23436056 | 0.93 | PADI4 (0.71) | PADI4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18969414 | 0.91 | PADI4 (0.67) | PADI4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18956444 | 0.91 | PADI4 (0.67) | PADI4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL28839537 | 0.91 | PADI4 (0.67) | PADI4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29850434 | 0.91 | PADI4 (0.67) | PADI4PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386590-B1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-06-02 | — | — | EP | disclosed |
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| WO-2017100594-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADI4, PADI1, PADI2 | PADI4 1/4885PDE4A 20/4885PDE4B 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.